Compare AMGN & SHOP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMGN | SHOP |
|---|---|---|
| Founded | 1980 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 181.7B | 191.3B |
| IPO Year | N/A | 2015 |
| Metric | AMGN | SHOP |
|---|---|---|
| Price | $319.45 | $162.83 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 14 | 32 |
| Target Price | ★ $315.31 | $162.22 |
| AVG Volume (30 Days) | 2.8M | ★ 7.8M |
| Earning Date | 02-03-2026 | 11-04-2025 |
| Dividend Yield | ★ 3.17% | N/A |
| EPS Growth | ★ 65.12 | 28.16 |
| EPS | ★ 12.93 | 1.36 |
| Revenue | ★ $35,971,000,000.00 | $10,696,000,000.00 |
| Revenue This Year | $10.85 | $31.76 |
| Revenue Next Year | $1.71 | $23.55 |
| P/E Ratio | ★ $24.57 | $121.14 |
| Revenue Growth | 10.56 | ★ 30.25 |
| 52 Week Low | $253.30 | $69.84 |
| 52 Week High | $346.38 | $182.19 |
| Indicator | AMGN | SHOP |
|---|---|---|
| Relative Strength Index (RSI) | 46.38 | 54.80 |
| Support Level | $312.39 | $159.10 |
| Resistance Level | $320.19 | $168.93 |
| Average True Range (ATR) | 6.87 | 5.91 |
| MACD | -3.82 | 1.12 |
| Stochastic Oscillator | 25.36 | 69.16 |
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Shopify offers an e-commerce platform primarily to small and medium-size businesses. The firm has two segments. The subscription solutions segment allows Shopify merchants to conduct e-commerce on a variety of platforms, including the company's website, physical stores, pop-up stores, kiosks, social networks (Facebook), and Amazon. The merchant solutions segment offers add-on products for the platform that facilitate e-commerce and include Shopify Payments, Shopify Shipping, and Shopify Capital.